Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. cardiology cardiovascular interventions
Show results for
Products
Services
Software
Training
Applications

Companies

News
Articles
Videos

Refine by
Date

  • Older

Cardiology Cardiovascular Interventions Articles & Analysis

27 news found

An Easy, Predictable, and Simpler Way to Embolize Tumors

An Easy, Predictable, and Simpler Way to Embolize Tumors

Instylla is now enrolling patients in a clinical trial for the world’s first hydrogel-based liquid embolic intended for the treatment of hypervascular tumors. A second initial application for its Embrace embolic therapy is hemorrhage control, where the product offers advantages in terms of simplicity, speed, and safety. Amar Sawhney and his teams, it seems, can make medical hydrogels do ...

ByInstylla, Inc.


Osso VR and American College of Cardiology to Develop Immersive Training for Cardiovascular Professionals

Osso VR and American College of Cardiology to Develop Immersive Training for Cardiovascular Professionals

Osso VR, now the largest and fastest-growing virtual reality (VR) company in healthcare, and the American College of Cardiology (ACC), a global nonprofit dedicated to transforming cardiovascular care, today announced a new collaboration to develop an immersive, VR-enabled training program for cardiovascular professionals. ...

ByOsso VR, Inc.


Belgian scale-up Oncomfort raises €10 million in Series A funding co-led by Debiopharm and Crédit Mutuel Innovation

Belgian scale-up Oncomfort raises €10 million in Series A funding co-led by Debiopharm and Crédit Mutuel Innovation

Oncomfort, the Belgian inventor of and leader in Digital Sedation - a new method for relieving patients’ pain and anxiety without medication - today announces the completion of a €10 million Series A funding round co-led by two prominent institutional investors: Debiopharm and Crédit Mutuel Innovation. Oncomfort plans to use this investment to further develop its innovative ...

ByOncomfort


Arterius Welcomes New Clinical Advisers

Arterius Welcomes New Clinical Advisers

Serruys is is a professor of Interventional Cardiology at the Interuniversity Cardiological Institute of the Netherlands (1988-1998), and Erasmus MC. ...

ByArterius Limited


Robocath achieves positive results in R-Evolution multicenter European clinical study on robotic coronary angioplasty

Robocath achieves positive results in R-Evolution multicenter European clinical study on robotic coronary angioplasty

100% clinical success rate: zero complications linked to robot up to 30 days post-procedure >95% technical success rate 84.5% average reduction in physician radiation exposure Robocath, a company that designs, develops and commercializes innovative robotic platforms for the treatment of vascular diseases, today presents the results of its R-Evolution clinical study at the international ...

ByRobocath


BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Study as Designed

BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Study as Designed

The FS procedure is a ranked analysis that compares occurrence of cardiovascular and other health-related events, along with functional capacity measures, through one year in patients receiving the study treatment to patients in the control arm who don’t receive the study treatment. ...

ByBiocardia, Inc.


Robocath concludes first European clinical study to demonstrate safety and efficacy of robotic coronary angioplasty performed with R-One

Robocath concludes first European clinical study to demonstrate safety and efficacy of robotic coronary angioplasty performed with R-One

Robocath, a company that designs, develops and commercializes innovative robotic platforms for the treatment of vascular diseases, announces today that it has concluded its ‘R-Evolution’ clinical study. The study was aimed at assessing the safety and efficacy of the R-OneTM robotic assistance platform. Sixty-two patients across six European hospital centers participated: the ...

ByRobocath


Robocath successfully completes first robotic coronary angioplasty with R-One in China

Robocath successfully completes first robotic coronary angioplasty with R-One in China

The procedure took place at the 301 Hospital in Beijing on November 24; performed by Dr. Yundai Chen, a renowned interventional cardiologist and author of several scientific publications. ...

ByRobocath


InspireMD Announces Publication of 12-Month Results of CGuard™ EPS SIBERIA Trial in Journals of the American College of Cardiology: Cardiovascular Interventions

InspireMD Announces Publication of 12-Month Results of CGuard™ EPS SIBERIA Trial in Journals of the American College of Cardiology: Cardiovascular Interventions

InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced that results from the investigator-initiated SIBERIA randomized clinical trial of CGuard EPS, that evaluated the peri-procedural and 30-day silent brain infarcts associated with the use of its ...

ByInspireMD Inc.


DurAVR accepted into TCT innovation session

DurAVR accepted into TCT innovation session

Anteris Technologies Ltd (ASX: AVR) (Anteris or the Company) announces its submission at this year’s Transcatheter Cardiovascular Therapeutics (TCT) conference at Orlando, Florida, United States was accepted into the innovation session. The TCT conference, running from November 4 to 6, is the largest and most prestigious Interventional ...

ByAnteris Technologies Limited


CARMAT appoints Ivo Simundic as Sales director for the DACH region to support the deployment of the Aeson artificial heart in Germany, Austria and Switzerland

CARMAT appoints Ivo Simundic as Sales director for the DACH region to support the deployment of the Aeson artificial heart in Germany, Austria and Switzerland

CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure, today announces the appointment of Ivo Simundic as Sales director for the DACH region (Germany, Austria and Switzerland). Graduated from ...

ByCarmat


BIOMODEX Technology Enables New Milestone in Interventional Cardiology

BIOMODEX Technology Enables New Milestone in Interventional Cardiology

BIOMODEX, the leader in bio-realistic haptic simulators for patient-specific rehearsal and physician training, today announced that its LAACS (Left Atrial Appendage Closure System) solution was used to perform a simulation ahead of a live case to be presented at the TVT Structural Heart Summit in Miami, FL. Physicians at the Montreal Heart Institute in Montreal, Quebec recently rehearsed the ...

ByBIOMODEX


First Five Patients Successfully Treated with atHeart Medical’s Novel reSept Atrial Septal Defect Occluder in U.S. IDE Pivotal Trial

First Five Patients Successfully Treated with atHeart Medical’s Novel reSept Atrial Septal Defect Occluder in U.S. IDE Pivotal Trial

atHeart Medical, a medical device company dedicated to establishing the new standard of care for closure of atrial septal defects (ASD), today announced the successful treatment of the first five patients in its ASCENT ASD U.S. Investigational Device Exemption (IDE) pivotal trial. This study, the company’s first in the US, will evaluate the safety and efficacy of the reSept ASD Occluder. ...

ByatHeart Medical


The long-term solution for stressed New York hearts

The long-term solution for stressed New York hearts

Avicenna Cardiology is located on Park Avenue in Manhattan, New York. The clinic is led by Dr. Azadeh Beheshtian, board certified in cardiovascular disease and internal medicine by the American Board of Internal Medicine. Dr. Beheshtian specializes in interventional cardiology and peripheral artery disease, providing top-quality ...

ByCoala Life Inc.


Alleviant Medical Announces Presentation of Clinical Data at American College of Cardiology and EuroPCR Conferences

Alleviant Medical Announces Presentation of Clinical Data at American College of Cardiology and EuroPCR Conferences

Results were presented at the American College of Cardiology Scientific Session (ACC.21) and at the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EuroPCR 2021) by Colin Barker, MD, Director of Interventional Cardiology at Vanderbilt University, Nashville, TN and Jacob ...

ByAlleviant Medical, Inc.


The Ultimate List of Attractive MedTech M&A Targets

The Ultimate List of Attractive MedTech M&A Targets

In 2020, the Journal of the American College of Cardiology: Cardiovascular Interventions published six-month results from a European multicenter post-market study demonstrating the safety and efficacy of the company’s CE-marked Peregrine System Infusion Catheter. ...

ByAnuncia Medical, Inc.


Robocath successfully completes first robotic coronary angioplasties in Belgium

Robocath successfully completes first robotic coronary angioplasties in Belgium

The Percutaneous Coronary Interventions (PCI) were performed on April 8 and 13 by Prof. Stefan Verheye, a recognized and highly experienced interventional cardiologist at ZNA Middelheim hospital in Antwerp, and his team. ...

ByRobocath


Newly Formed Company, atHeart Medical, Aims to Evolve Septal Closure with the reSept ASD Occlude

Newly Formed Company, atHeart Medical, Aims to Evolve Septal Closure with the reSept ASD Occlude

atHeart Medical, a medical device company dedicated to establishing the new standard of care for closure of atrial septal defects (ASD), announced today that it has commenced operations and is initiating its U.S. Investigational Device Exemption (IDE) trial. The company is led by seasoned global medtech executive, Laurent Grandidier, with support from an exceptional management team that has ...

ByatHeart Medical


ELIXIR MEDICAL ANNOUNCES OUTSTANDING 24-MONTH DATA FOR DYNAMX CORONARY BIOADAPTOR SYSTEM, DEMONSTRATING STRONG SAFETY WITH NO TARGET LESION REVASCULARIZATION, MYOCARDIAL INFARCTION OR THROMBOSIS THROUGH 24 MONTHS

ELIXIR MEDICAL ANNOUNCES OUTSTANDING 24-MONTH DATA FOR DYNAMX CORONARY BIOADAPTOR SYSTEM, DEMONSTRATING STRONG SAFETY WITH NO TARGET LESION REVASCULARIZATION, MYOCARDIAL INFARCTION OR THROMBOSIS THROUGH 24 MONTHS

The results were presented at the 30th Annual Live Interventions in Vascular Endotherapy conference organized by the National Heart Centre of Singapore (Singapore LIVE). ...

ByElixir Medical Corporation


Robocath successfully carries out Europe’s first remote robotic-assisted coronary angioplasty

Robocath successfully carries out Europe’s first remote robotic-assisted coronary angioplasty

Watch the video of the Europe’s first remote robotic-assisted coronary angioplasty Prof. Rémi Sabatier, Interventional Cardiologist at Caen University Hospital and Associate Professor in Remote Medicine said: “There are still significant disparities in the level of care for cardiovascular diseases depending on where a patient lives. ...

ByRobocath

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT